sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis

Figure 1 Association of soluble triggering receptor expressed on myeloid cell-1 at admission with prognosis and organ failure in patients with acute decompensation of cirrhosis. A: Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1) distribution in study cohort (median with interquartile range); B: Survival rates after 1-year (365-d) of patients in the “high” and “low” sTREM-1 groups in the study and validation cohorts; C: Soluble CD14 subtype (sCD14-ST) distribution in study cohort (median with interquartile range); D: Prediction of 1-year mortality according to sTREM-1, sCD14-ST, white blood cell, C-reactive protein and procalcitonin; E: sCD14-ST or sTREM-1 Levels according to the numbers of failed organs; F: sTREM-1 distribution of patients with and without liver, coagulation, kidney, or cerebral failure. ^aP < 0.05, ^cP < 0.001. ACLF: Acute-on-chronic liver failure; CRP: C-reactive protein; PCT: Procalcitonin; sCD14-ST: Soluble CD14 subtype; sTREM-1: Soluble triggering receptor expressed on myeloid cell-1; STU: Study; VLD: Validation; WBC: White blood cell.